-

LivaNova to Present at Piper Sandler Healthcare Conference in December

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Alex Shvartsburg, Chief Financial Officer, will present a general business update during a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City. The presentation will take place on Tues., Dec. 2, at 1:30 p.m. Eastern Standard Time.

The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup of the webcast. A replay will be available on the LivaNova website within 24 hours after the live presentation.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a vision to change the trajectory of lives for a new day. Through ingenious medical solutions in select neurological and cardiac conditions, LivaNova strives to ignite patient turnarounds. Headquartered in London, with approximately 3,000 employees and a presence in more than 100 countries, LivaNova serves patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding participation in upcoming events. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contacts

LivaNova Investor Relations and Media Contacts
+1 281-895-2382
Briana Gotlin
VP, Investor Relations
InvestorRelations@livanova.com
Deanna Wilke
VP, Corporate Communications
Corporate.Communications@livanova.com

LivaNova PLC

NASDAQ:LIVN
Details
Headquarters: London, United Kingdom
CEO: Vladimir Makatsaria
Employees: 3000
Organization: PUB
Revenues: $1.25B (2024)
Net Income: $63.2M (2024)

Release Versions
$Cashtags

Contacts

LivaNova Investor Relations and Media Contacts
+1 281-895-2382
Briana Gotlin
VP, Investor Relations
InvestorRelations@livanova.com
Deanna Wilke
VP, Corporate Communications
Corporate.Communications@livanova.com

Social Media Profiles
More News From LivaNova PLC

LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) assigned VNS Therapy™, a LivaNova neuromodulation treatment for patients 4 years of age and older with Drug-Resistant Epilepsy (DRE) and focal seizures, to New Technology Ambulatory Payment Classification (APC) 1580 for new patient implants (NPIs) under the 2026 Medicare Hospital Outpatient Prospective Payment System....

LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic roadmap and long-range financial plan. “We are confident in our ability to deliver on the targets we outlined today. LivaNova’s talented team is focused on a revitalized innovation strategy and operational excellence,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova. “The leadership positions we hold in our...

LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2025 and raised full-year 2025 guidance. Financial Summary and Highlights(1) Third-quarter revenue of $357.8 million increased 12.5% on a reported basis, 11.0% on a constant-currency basis, and 12.5% on an organic basis as compared to the prior-year period Third-quarter U.S. GAAP diluted earnings per share of $0.49 and adjusted dilut...
Back to Newsroom